Up-date on the treatment of serious fungal infections;Actualización sobre el tratamiento de las infecciones fúngicas graves

Revista Espanola de Quimioterapia

Volumn 21, Issue SPEC. ISS. 1, 2008, Pages 14-25

  Sá, Márcio Borges ^a  

^a HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Antifungal therapy; Candidemia; Invasive aspergilosis; Invasive fungal infections; Pre emptive treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CRITICALLY ILL PATIENT; DISEASE COURSE; DRUG ANTAGONISM; DRUG INDICATION; DRUG POTENTIATION; EARLY DIAGNOSIS; EARLY INTERVENTION; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; RISK ASSESSMENT; RISK FACTOR;

ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MYCOSES; SEVERITY OF ILLNESS INDEX;

EID: 55049085390     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Ostrosky-Zeichner L, Pappas G. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-63.
2. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ. et al. Guidelines for treatment of candidiasis. Clinl Infect Dis 2004;38:161-89.
3. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
4. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44:1782-7.
5. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev 2007;20: 133-63.
6. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29:253-8.
7. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-86.
8. Tortorano AM, Caspani L, Rigoni AL, Biraghi E, Sicignano A, Viviani MA. Candidosis in the intensive care unit: a 20 year survey. J Hosp Infect 2004;57:8-13.
9. Jorda-Marcos R, Álvarez-Lerma F, Jurado M, Palomar M, Nolla-Salas J, León MA, et al and the EPCAN Study Group. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007;50:302-10.
10. Olaechea PM, Palomar M, León-Gil C, Álvarez-Lerma F, Jorda R, Nolla-Salas J, et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004;23:323-30.
11. a ed. Silva, 2006.
12. Morrell M, Fraser VJ, Kollef MJ. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob Agents Chemother 2005;49:3640-5.
13. Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucía P, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997;23:23-30.
14. Garnacho-Montero J, García-Garmendia JL, Barrero-Almodóvar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51.
15. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3:772-85.
16. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in Candida bloodstream infections: results from population-based surveillance, Barcelona (Spain), 2002-2003. J Clin Microbiol 2005;43:1829-35.
17. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002;113:480-5.
18. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003;18:166-77.
19. a ed. Barcelona: Edikamed, 2003; p. 121-33.
20. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: an approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005;43:235-43.
21. Pelz RK, Hendrix CV, Swoboda CM, Diener-West M, Merz WG, Hammond J, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
22. Cruciani M, De Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005;31: 1479-87.
23. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27: 1066-72.
24. Ables AZ, Blumen NA, Valainis GT, et al. Fluconazole prophylaxis of severe Candida infection in trauma y postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000;9:169-75.
25. Krcmery VC Jr, Babela R. Candidemia in the surgical intensive care unit. Clin Infect Dis 2002;34:1537-8.
26. Borges M, Morales R. Peritonitis grave y uso de antifúngicos: profilaxis, terapia empirica y anticipada. ¿qué deben hacer? Med Intensiva 2006;4:29-37.
27. Lipsett PA. Surgical critical care: Fungal infections in surgical patients. Crit Care Med 2006;34(Suppl. 9):S215-24.
28. Solomkin J, Mazuski J, Baron E, Sawer R, Nathens A, DiPiro J, et al. CID 2003;37:997-1005.
29. Tellado JM, Sitges-Sierra A, Barcenilla F, Palomar M, Serrano R, Barberán J, et al. Rev Esp Quimioterap 2005;18:179-86.
30. Gleason TG, May AK, Caparelli D, et al. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997;132:1197-202.
31. Liebana A. Manifestaciones clínicas de la aspergilosis nosocomial. Rev Iberoamericana Micología 17;2000:85-9.
32. Muñoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000;15:83-90.
33. Zaragoza R, Mariscal F. Tratamiento de la candidiasis en enfermos críticos no neutropénicos: papel de la anfotericina lipídica. Med Intensiva 2007 [en prensa].
34. Nolla Salas J, Rodríguez A, Olaechea Astigarraga PM, Prieto Prieto J, Almirante Gragera B. Epidemiología de la infección fúngica en el paciente crítico no granulocitopénico. Med Intensiva 2005;3(Suppl.):4-11.
35. Galván B, Mariscal F. Epidemiologia de la candidemia en UCI. Rev Iberoam Micol 2006;23:2-15.
36. Tortorano AM, Pemán J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. and the ECMM Working Group on Candidaemia. Epidemiology of Candidaemia in Europe: results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study. Eur J Clin Microbiol Infect Dis 2004;23:317-22.
37. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007;35:1077-83.
38. Hadley S, Lee WW, Ruthazer R, Nasraway SA. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients. Crit Care Med 2002:30:1808-14.
39. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
40. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003;31:752-7.
41. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Álvarez-Lerma F, et al. A bedside scoring system (Candida score) for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-7.
42. Ruiz-Santana S, León C, Saavedra P, Galván B, Utande A, Blasco M, et al. and Cava Study Group. Validation Study of the Candida score for discriminating between Colonization an Invasive Candidiasis in Non-Neutropenic Critically III Patients. Abstract M-1167. En: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007; Chicago, 2007.
43. Ruiz-Santana S, Castro C, Saavedra P, León C, Martín Mazuelos E, Blanco A, et al. and Cava Study Group. (1,3)-β-D-glucan and Candida score in discriminating between Colonization and Invasive Candidiasis Non-Neutropenic Critically ill Patients. Abstract M-563. En: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007. Chicago, 2007.
44. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32:2443-9.
45. Borges M, Pemán J. Tratamiento antifúngico combinado en pacientes críticos: perspectivas futuras. Med Intensiva 2007;31: 521-6.
46. Zaragoza A, Pemán J. Diagnostic and therapeutic approach to fungal infections in critical care settings: different options but the same strategy J Invasive Fungal Infect 2007;1:50-8.
47. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park) 2004;18 (13 Suppl. 7):24-9.
48. Steinbach. CID. 2003;37:188.
49. Rex JH, Pappas PG, et al. Clin Infect Dis 2003;36:1221-8.
50. Marr. CID 2004;39:797-802.
51. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81:320-6.
52. Garnacho J, León C, Almirante B, Álvarez F, Cuenca Estrella M, García Rodríguez JA, et al. Recomendaciones terapéuticas en el PCNN. Conferencia de Consenso. Medicina Intensiva 2005;3; 43-52.
53. León C, Rello J, Ruiz-Santana S, León C, Martin M. Planteamiento terapéutico antifúngico empírico en pacientes críticos. Med Intensiva 2007;31:375-87.
54. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis. 2005;40 (Suppl. 6): S384-91.
55. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320.
56. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
57. Kuse ER, Chetchotisakd P, Da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27.
58. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin Study Group Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82.
59. Vázquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-22.
60. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42.
61. Zaragoza Crespo R, Luque Gómez P. Voriconazol en UCI: ¿Cuáles son sus indicaciones, ventajas, precauciones y contraindicaciones reales? Med Intensiva 2006;4;S11-18.
62. Pemán J, Salavert M, Cantón E, Jarque I, Roma E, Zaragoza R, et al. Voriconazole in the management of nosocomial invasive fungal infections. Therapeutics and Clinical Risk Management 2006;2:1-30.
63. Álvarez-Lerma F, Nicolás-Arfelis JM, Rodríguez-Borregán JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother 2005;17:417-27.
64. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
65. Samonis G, Gikas A, Anaissie EJ, Vrenzos G, Maraki S, Tselentis Y, et al. Prospective evaluation of effects of broad spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993;37:51-3.